

The attached chart is a proposed program funding timeline for the remaining funds to be committed (approximately \$1,562,900,000). Each year, the Governing Board should be presented the financial strategic plan to allow for reexamination and reallocation of priorities. This chart is solely for purposes of discussion and provides a basic backbone and overview of the Agency's program in years 2011 to 2017.

The estimated funds available for program commitments in years 2011-2107 is calculated as follows:

\$	3,000,000,000	Total General Obligation Bond Authorized
\$	1,177,100,000	Estimated Commitments thru December 2010
\$	180,000,000	General & Grants Administration
\$	50,000,000	Capitalized Interest/Cost of Issuance
\$	30,000,000	General reserves and direct legal costs
<u>\$</u>	<u>1,437,100,000</u>	<u>Total estimated committed funds, operations, and general reserves/direct legal costs</u>

<b>\$</b>	<b>1,562,900,000</b>	<b>Estimated funds available for program commitments (2011-2017)</b>	
-----------	----------------------	--	--

**PROPOSED RFA FUNDING TIMELINE 2011-2017**

RFA	Governing Board Estimated Approval Date**	Calendar Year that Funding Starts	Estimated Commitment Amount
Tools and Technology 2*	Jan-Mar 2011	2011	\$40,000,000
Research Leadership 4*	Jan-Mar 2011	2011	\$5,600,000
Clinical Trials*	Apr-June 2011	2011	\$50,000,000
Research Leadership 5*	Apr-June 2011	2011	\$5,600,000
Basic Biology 3*	July-Sept 2011	2011	\$45,000,000
Research Leadership 6*	July-Sept 2011	2011	\$5,600,000
Disease Team 2 Planning*	July-Sept 2011	2011	\$3,300,000
Research Leadership 7 & 8* <sup>a</sup>	Oct-Dec 2011	2011	\$11,200,000
Shared Labs 2	Oct-Dec 2011	2012	\$30,000,000
<b>Total Committed Funds 2011</b>			<b>\$196,300,000</b>
Early Translational 3	Jan-Mar 2012	2012	\$80,000,000
Bridges 2	Apr-June 2012	2012	\$25,000,000
Training 3	Apr-June 2012	2012	\$45,000,000
Disease Team 2 Award*	Apr-June 2012	2012	\$240,000,000
Basic Biology 4	Oct-Dec 2012	2013	\$45,000,000
<b>Total Committed Funds 2012</b>			<b>\$435,000,000</b>
Tools and Technology 3	Jan-Mar 2013	2013	\$30,000,000
IPS - banking	Jan-Mar 2013	2013	\$25,000,000
Early Translational 4	Apr-June 2013	2013	\$80,000,000
Disease Team 3 Planning	July-Sept 2013	2013	\$3,300,000
To Be Determined 1	Oct-Dec 2013	2014	\$30,000,000
<b>Total Committed Funds 2013</b>			<b>\$168,300,000</b>
Basic Biology 5	Jan-Mar 2014	2014	\$35,000,000
Disease Team 3 Award	July-Sept 2014	2014	\$200,000,000
Early Translational 5	July-Sept 2014	2014	\$60,000,000
To Be Determined 2	Oct-Dec 2014	2015	\$30,000,000
<b>Total Committed Funds 2014</b>			<b>\$325,000,000</b>
Basic Biology 6	Jan-Mar 2015	2015	\$35,000,000
Disease Team 4 Planning	July-Sept 2015	2015	\$3,300,000
To Be Determined 3 <sup>b</sup>	July-Sept 2015	2015	\$85,000,000
Floating Reserve <sup>b</sup>	July-Sept 2015	2015	\$50,000,000
Early Translational 6	Oct-Dec 2015	2016	\$60,000,000
<b>Total Committed Funds 2015</b>			<b>\$233,300,000</b>
To Be Determined 4 b	Apr-June 2016	2016	\$35,000,000
Disease Team 4 Award	July-Sept 2016	2016	\$200,000,000
To Be Determined 5 <sup>c</sup>	July-Sept 2016	2016	\$30,000,000
<b>Total Committed Funds 2016</b>			<b>\$265,000,000</b>
To Be Determined 6 <sup>c</sup>	Jan - Mar 2017	2017	\$40,000,000
To Be Determined 7 <sup>c</sup>	Apr- June 2017	2017	\$40,000,000
To Be Determined 8 <sup>c</sup>	Apr- June 2017	2017	\$50,000,000
<b>Total Committed Funds 2017</b>			<b>\$130,000,000</b>
<b>Total RFA Cashflow Commitments including \$190M Estimated Recovered Funds (2011-2017)</b>			<b>\$1,752,900,000</b>
<b>Total Net Funds Available for Cash Flow Commitments of \$190M Recovered Funds (2011-2017)</b>			<b>\$1,562,900,000</b>

<sup>a</sup> Research Leadership Award funds all likely expended in calendar year 2011

<sup>b</sup> TBD funds can be designated into one or more RFAs and a \$50M floating reserve fund can supplement any program as appropriate

<sup>c</sup> Estimated undisbursed funds of \$190M is divided into \$60M for 2016 and \$130M for 2017

<sup>bc</sup> Candidate categories that the President wishes to discuss with the Board include programs such as alpha stem cell clinic program, a stem cell genomics program, and additional funds for clinical trials.

\* Concept Approved RFA's

\*\*Cash Disbursements Start Approx. 3 Months Post Governing Board Approval